Malignant ascites: pathophysiology and treatment

[1]  F. Zhu,et al.  A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study , 2012, Journal of Gastrointestinal Cancer.

[2]  P. Benedetti‐Panici,et al.  Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View , 2011, Clinical & developmental immunology.

[3]  G. Rustin,et al.  Recurrent Ovarian Cancer: When and How to Treat , 2011, Current oncology reports.

[4]  C. Garrett,et al.  Cetuximab in the treatment of patients with colorectal cancer , 2011, Expert opinion on biological therapy.

[5]  J. Sakamoto,et al.  Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer , 2011, Gastric Cancer.

[6]  P. Ravenda,et al.  Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  C. Bokemeyer,et al.  Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. , 2010, Cancer treatment reviews.

[8]  D. Elias,et al.  Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  P. Murawa,et al.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.

[10]  S. Hur,et al.  Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer , 2010, Journal of surgical oncology.

[11]  H. Dickinson,et al.  Management of drainage for malignant ascites in gynaecological cancer. , 2010, The Cochrane database of systematic reviews.

[12]  T. Chua,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Bokemeyer,et al.  Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? , 2009, The oncologist.

[14]  A. Garofalo,et al.  Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi‐institutional retrospective analysis in 52 patients , 2009, Journal of surgical oncology.

[15]  Michael J. Miller,et al.  Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. , 2009, Journal of pain and symptom management.

[16]  G. Scambia,et al.  Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. , 2009, Gynecologic oncology.

[17]  T. Chua,et al.  Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and Mortality , 2009, Annals of surgery.

[18]  L. Graziosi,et al.  [Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report]. , 2009, Il Giornale di chirurgia.

[19]  M. Saif,et al.  Management of ascites due to gastrointestinal malignancy. , 2009, Annals of Saudi medicine.

[20]  S. Msika,et al.  Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  L. Stokes,et al.  Percutaneous Management of Malignant Fluid Collections , 2007, Seminars in interventional radiology.

[22]  R. Kimmig,et al.  Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study , 2007, Clinical Cancer Research.

[23]  K. El-Shami,et al.  Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites , 2007 .

[24]  P Tappenden,et al.  Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. , 2007, Health technology assessment.

[25]  T. Sielaff,et al.  Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery , 2006, Journal of Gastrointestinal Surgery.

[26]  D. Querleu,et al.  Pharmacokinetics of Oxaliplatin During Open Versus Laparoscopically Assisted Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC): An Experimental Study , 2007, Annals of Surgical Oncology.

[27]  P. Sugarbaker,et al.  Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  G. Becker,et al.  Malignant ascites: systematic review and guideline for treatment. , 2006, European journal of cancer.

[29]  J. Sakamoto,et al.  A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. , 2005, Japanese journal of clinical oncology.

[30]  A. Covey.  Management of malignant pleural effusions and ascites. , 2005, The journal of supportive oncology.

[31]  D. Kelsen,et al.  Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma , 2005, Journal of Cancer Research and Clinical Oncology.

[32]  R. Omary,et al.  Comparison of percutaneous management techniques for recurrent malignant ascites. , 2004, Journal of vascular and interventional radiology : JVIR.

[33]  Y. Adam,et al.  Malignant ascites: past, present, and future. , 2004, Journal of the American College of Surgeons.

[34]  P. Brown.  Matrix metalloproteinase inhibitors , 2004, Breast Cancer Research and Treatment.

[35]  G. Jayson,et al.  The current and future management of malignant ascites. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

[36]  D. Morris,et al.  Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. , 2003, Anticancer research.

[37]  Ted D. Barnett,et al.  Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites: a simplified percutaneous approach. , 2002, Journal of vascular and interventional radiology : JVIR.

[38]  A. Rosemurgy,et al.  Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Sherer,et al.  The Role of Angiogenesis in the Accumulation of Peritoneal Fluid in Benign Conditions and the Development of Malignant Ascites in the Female , 2000, Gynecologic and Obstetric Investigation.

[40]  D. Hicklin,et al.  VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[41]  M Nakajima,et al.  [Matrix metalloproteinase inhibitors]. , 2000, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[42]  P. McNamara,et al.  Paracentesis – an effective method of symptom control in the palliative care setting? , 2000, Palliative medicine.

[43]  Gordon B. Mills,et al.  Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites , 1999, Annals of Surgical Oncology.

[44]  T. Morisaki,et al.  The past, the present and future of the OK-432 therapy for patients with malignant effusions. , 1998, Anticancer research.

[45]  W. Faught,et al.  A survey of practice in management of malignant ascites. , 1998, Journal of pain and symptom management.

[46]  R. Steele,et al.  Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[47]  Y. Yamaguchi,et al.  Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. , 1995, Anticancer research.

[48]  S. Sharma,et al.  Management of symptomatic malignant ascites with diuretics: two case reports and a review of the literature. , 1995, Journal of pain and symptom management.

[49]  P. Brown.  Matrix metalloproteinase inhibitors: a novel class of anticancer agents. , 1995, Advances in enzyme regulation.

[50]  R. Coombes,et al.  A pilot study of intraperitoneal cisplatin in the management of gastric cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  M. Engelhard,et al.  Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  R. Buckman,et al.  Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3 , 1992, Gynecologic oncology.

[53]  P. Pockros,et al.  Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. , 1992, Gastroenterology.

[54]  N. Gebbia,et al.  Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy. , 1991, In vivo.

[55]  R. Schilsky,et al.  Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Slevin,et al.  The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. , 1988, British Journal of Cancer.

[57]  J. Llach,et al.  Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. , 1988, Gastroenterology.

[58]  W. Jiménez,et al.  Comparison of Paracentesis and Diuretics in the Treatment of Cirrhotics With Tense Ascites , 1987 .

[59]  W. Jiménez,et al.  Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. , 1987, Gastroenterology.

[60]  S. Bruno,et al.  Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy. , 1987, Journal of hepatology.

[61]  V. Arroyo,et al.  PARACENTESIS VERSUS DIURETICS IN THE TREATMENT OF CIRRHOTICS WITH TENSE ASCITES , 1985, The Lancet.

[62]  H. Itoh,et al.  New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. , 1983, Surgery.

[63]  L. Salmela,et al.  On the treatment and prognosis of malignant ascites: Is the survival time determined when the abdominal paracentesis is needed? , 1982, Journal of surgical oncology.

[64]  M. Katano,et al.  Neutrophil‐Mediated Tumor Cell Destruction in Cancer Ascites , 1982, Cancer.

[65]  F. Flickinger,et al.  Intracavitary chromic phosphate (32p) colloidal suspension therapy , 1981, Cancer.

[66]  H. D. Kuntz.  ["Malignant" ascites]. , 1981, MMW, Munchener medizinische Wochenschrift.

[67]  R. Kefford,et al.  INTRACAVITARY ADRIAMYCIN NITROGEN MUSTARD AND TETRACYCLINE IN THE CONTROL OF MALIGNANT EFFUSIONS: A RANDOMIZED STUDY , 1980, The Medical journal of Australia.

[68]  V. Devita,et al.  Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. , 1980, Cancer research.

[69]  B. A. Lond,et al.  Andrew Moynihan Claye. , 1977, Lancet.

[70]  H. Brincker,et al.  Intracavitary thiotepa in malignant pleural and peritoneal effusions. , 1968, Acta radiologica: therapy, physics, biology.

[71]  G. Pack,et al.  Intracavitary administration of radioactive isotopes in the control of effusions due to cancer: Results in 267 patients , 1966, Cancer.

[72]  S. W. Nelson,et al.  Department of radiology , 1966 .

[73]  H. Groesbeck,et al.  Intracavitary thio-TEPA for malignant effusions. , 1962, The American surgeon.

[74]  J. Storaasli,et al.  Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. , 1955, Journal of the American Medical Association.